AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

• AWS launched Amazon Bio Discovery, a no-code AI platform letting scientists run drug-design workflows using foundation models plus an AI agent, cutting months of research into weeks.
• In a Memorial Sloan Kettering/Twist Bioscience collaboration, nearly 300,000 AI-designed antibodies were narrowed to 100,000 for physical lab testing.
• Bayer, Broad Institute and Voyager Therapeutics are early adopters, and 19 of the top 20 global pharma companies already use AWS cloud services.
• AWS is separately partnering with Boston Consulting Group and Merck on an AI tool to improve clinical trial site selection.